David
Lloyd hails from Dublin, Ireland, and gained his primary B.Sc.
in applied chemistry and later his Ph.D. in the design and
synthesis of novel antimalarial agents from Dublin City University.
On graduation he moved to Trinity College Dublin where he
was appointed Research Fellow in Pharmaceutical Chemistry
in the School of Pharmacy, working extensively on the rational
design of antiestrogenic ligands and the development of novel
apoptotic compounds. In 2001 David moved to Cambridge in the
UK to join De Novo Pharmaceuticals as a Senior Scientist in
the Applied Design drug discovery group. David currently heads
De Novo’s ligand-based design discovery program.
|
